Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2007-01-30
2007-01-30
Russe, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S649000, C514S006900, C514S021800
Reexamination Certificate
active
10747855
ABSTRACT:
The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized glutathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can be present in a ratio of 3000 to 1 and preferably 1000 to 1. The oxidized glutathione-based compound can be oxidized glutathione itself or salts or derivatives. A feature of the invention is that the composite has a more stabilized disulfide bond than the oxidized glutathione-based compound itself. Methods for preparing the composite are provided, such methods being beneficial in that the composite is provided in high yields and at high purity. Methods for treating various medical conditions with the composites of the present invention are also disclosed.
REFERENCES:
patent: 4550022 (1985-10-01), Garabedian et al.
patent: 4761399 (1988-08-01), Pilotto et al.
patent: 4871528 (1989-10-01), Tognella et al.
patent: 4927808 (1990-05-01), Kitahara et al.
patent: 4968671 (1990-11-01), Asano et al.
patent: 5104852 (1992-04-01), Kralick et al.
patent: 5206220 (1993-04-01), Hilton
patent: 5208249 (1993-05-01), Rowe et al.
patent: 5223488 (1993-06-01), Ogata et al.
patent: 5248697 (1993-09-01), Wilmore
patent: 5352771 (1994-10-01), Kostic et al.
patent: 5789000 (1998-08-01), Hausheer et al.
patent: 5916878 (1999-06-01), Kolobov et al.
patent: 5977073 (1999-11-01), Khaled
patent: 6013632 (2000-01-01), Jones et al.
patent: 6159500 (2000-12-01), Demopoulos et al.
patent: 6165979 (2000-12-01), Kozhemyakin et al.
patent: 6251857 (2001-06-01), Kozhemyakin et al.
patent: 6312734 (2001-11-01), Kozhemyakin et al.
patent: 6492329 (2002-12-01), Kozhemyakin et al.
patent: 0 265 719 (1988-05-01), None
patent: 0502313 (1992-09-01), None
patent: 616803 (1994-09-01), None
patent: 764442 (1997-03-01), None
patent: 62-221698 (1987-09-01), None
patent: 4-9336 (1992-01-01), None
patent: 10-59839 (1998-03-01), None
patent: WO 92/021368 (1992-12-01), None
patent: WO 94/00141 (1994-01-01), None
patent: WO 96/40205 (1996-12-01), None
patent: WO 97/21443 (1997-06-01), None
patent: WO 97/21444 (1997-06-01), None
patent: WO 00/31120 (2000-06-01), None
patent: WO 2004/024062 (2004-03-01), None
Raggi et al. Spectrophotometric determination of thiols . . . Pharmazie. 1998, vol. 53, No. 4, pp. 239-242.
Raggi et al. Studia della cinetica di reazione . . . Boll. Chim. Farmuccurico. 1992, vol. 131, No. 8, pp. 318-319.
C.D. Gregory, “Apoptosis: a role in neoplasia?”, Cell Proliferation in Cancer Regulatory Mechanisms of Neplastic Cell Growth, L. Pusztai & C.E. Lewis editors, Oxford University Press, Chapter 13, pp. 342-359, 1996.
Lempers, et al., Reactions of [P+CL (dien)] CL with Glutathione . . . , Inorg. Chim. Acta. vol. 152, pp. 201-207, 1988.
Ohta, et al., Reaction of oxidized glutathione . . . , Int. J. Pharmaceutics vol. 161, pp. 15-21, 1998.
Raggi, et al. Spectrophotometric determination of thiols . . . , Pharmazie. vol. 53, No. 4, pp. 239-242, 1998.
Raggi, et al., Studio della cinetica di reazione . . . , Boll. Chim. Farmaccurico. vol. 131, No. 8, pp. 318-319, 1992.
A. Szent-Györgyi, “Charge Transfer and Electronic Mobility,” Biochemistry, vol. 58, pp. 2012-2014, 1967.
D.L. Vaux & A. Strasser, “The molecular biology of apoptosis,” Proceedings of the National Academy of Sciences, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 2239-2244, Mar. 1996.
Ahmed, K.A., et al., “Nonenzymic Reactivation of ReducedBovine Pancreatic Ribonuclease by Air Oxidation and by Glutathione Oxidoreduction Buffers,”The Journal of Biological Chemistry, vol. 250, No. 21, pp. 8477-8482 (1975).
Araie, M., et al., “Effect of Oxidized Glutathione on the Barrier Function of the Corneal Endothelium,”Investigative Ophthalmology & Visual Science, vol. 29, pp. 1884-1887 (1988).
Aukrust, P., et al., “Increased Levels of Oxidized Glutathione in CD4+Lymphocyted Associated With Disturbed Intracellular Redox Balance in Human Immunodeficiency Virus Type 1 Infection,”Blood, vol. 86, No. 1, pp. 258-267 (1995).
Barbato, G., et al., Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain,The EMBO Journal, vol. 19, No. 6, pp. 1195-1206 (2000).
Barot-Ciorbaru, R., et al., “Immunomodulators from Nocardia opaca,”Forum on immunomodulators, pp. 63-77 (1995).
Beckett, G. J., et al., “Glutathione S-Transferases: Biomedical Applications,”Advances in Clinical Chemistry, vol. 30, pp. 281-381 (1993).
Beutler. E., “Nutritional and Metabolic Aspects of Glutathione,”Annu. rev. Nutr., vol. 9, pp. 287-302 (1989).
Blight, K.L., et al., “Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets,”Antiviral Therapy, vol. 3, pp. 71-81 (1998).
Bloy, C., et al., “RU 41740 (Biostim), an immunomodulating agent from bacterial origin,”Forum on immunomodulators, pp. 85-100 (1995).
Bouffard, P., et al., “Anin VitroAssay for Hepatitis C Virus NS3 Serine Proteinase,” Virology, vol. 209, pp. 52-59 (1995).
Butkiewicz, N, et al., “Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3,”Journal of Virology, vol. 74, No. 9, pp. 4291-4301 (2000).
Butkiewicz, N. J., et al., “Hepatitis C NS3 Protease: Restoration of NS4A Cofactor Activity by N-Biotinylation of Mutated NS4A Using Synthetic Peptides,”Biochemical and Biophysical Research Communications, vol. 267, pp. 278-282 (2000).
Calabrese, F., et al., “Liver cell Apoptosis in Chronic Hepatitis C Correlates With Historical But Not Biochemical Activity or Serum HCV-RNA Levels,”Hepatology, vol. 31, No. 5, pp. 1153-1159 (2000).
Carreno, V., et al., “A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B*,”Journal of Hepatology, vol. 32, pp. 317-324 (2000).
Cerretani, M., et al., “A High-Throughput Radiometric Assay for Hepatitis C Virus NS3 Protease,”Analytical Biochemistry, vol. 266, pp. 192-197 (1999).
Chen, M., et al., “Human Murine Antibody Recognition is Focused on the ATPase/Helicase, But Not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein,”Hepatology, vol. 28, pp. 219-224 (1998).
Cirelli, R., et al., “Interferons in human papilomavirus infections,”Antiviral Research, vol. 24, pp. 191-204 (1994).
Cohen, G., “Enzymatic/Nonenzymatic Sources of Oxyradicals and Regulation of Antioxidant Defenses,”Annals New York Academy of Sciences, pp. 8-14. (not dated).
De Flora, S., et al., “Antioxidant Activity and Other Mechanisms of Thiols Involved in Chemoprevention of Mutation and Cancer,”The American Journal of Medicine, vol. 91, pp. 122-130 (1991).
Devlin, et al., “Glutathione, Amino Acid Metabolism II: Metabolism of the Individual Amino Acids,”Textbook of Biochemistry with Clinical Correlations, 3rdEdition, pp. 522-528 (1992).
Dienstag, J. L., et al., “Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States,”The New England Journal of Medicine, vol. 341, No. 17, pp. 1256-1263 (1999).
Dillman, R. O., “The Clinical Experience with Interleukin-2 in Cancer Therapy,”Cancer Biotherapy, vol. 9, No. 3, pp. 183-209 (1994).
Droge, W., et al., “Functions of glutathione and glutathione disulfide in immunology and immunopathology,”The FASEB Journal, vol. 8, pp. 1132-1138 (1994).
Estrela, J.M., et al., “Regulation of glutathione metabolism in Ehrilch ascites tumour cells,”Biochem. J., vol. 286, pp. 257-262 (1992).
Fabris, P., et al., “TTV infection in patients with acute hepatitis of defined aetiology and in acute non-A-E hepatitis,”Journal of Hepatology, vol. 32, pp. 661-665 (2000).
Fan, X.G., et al., “Circulating Th 1 and Th2 cytokines in
Balasovski Mark B.
Kozhemyakin Leonid A.
Novelos Therapeutics, Inc.
Russe Jeffrey Edwin
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods for production of the oxidized glutathione composite... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for production of the oxidized glutathione composite..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for production of the oxidized glutathione composite... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781556